Gilead Sciences

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024
Obesity, Merck & Co., MRI, LAS, Weight loss, Fatty liver disease, Type 2 diabetes, Magnetic resonance imaging, Insulin resistance, NASH, FFAR4, Liver, Liver disease, Diabetes, Alcoholic liver disease, Therapy, Hypertension, PPAR, Eli Lilly and Company, Gilead Sciences, Chronic pain, Disease, Inflammation, FASN, AstraZeneca, Novo Nordisk, FXR, Prevalence, CCR5, FGF, Physical examination, Weakness, Bronchial thermoplasty, Cilofexor, Metabolic syndrome, Mitsubishi Tanabe Pharma, Development, NAFLD, Risk, Fibrosis, Fatigue, Dyslipidemia, USD, Non-alcoholic fatty liver disease, Merck, Pharmaceutical industry

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer

Retrieved on: 
Tuesday, January 16, 2024
Biotechnology, Pharmaceutical, Health, Oncology, Death, Patient, ECOG, SCA, OS, Liver disease, ASCO, Survival, History, University, Society, Dassault Group, CD73, Gilead Sciences, Toxicity, Master of Science, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences.

Key Points: 
  • Arcus Biosciences, Inc. (NYSE:RCUS) today announced promising overall survival data from ARC-8, a Phase 1b study that is being co-developed with Gilead Sciences.
  • The results will be presented during the 2024 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI).
  • Median overall survival (mOS) data for both quemliclustat-based regimens were numerically greater than historical benchmark data for chemotherapy alone, which has shown a mOS of approximately nine months.
  • The efficacy data for the pooled dose-escalation, dose-expansion and randomized arms, as well as the data from the SCA, are summarized below:

Global Pseudomonas Aeruginosa Infection Treatment Market Report 2023 and 2024-2030: North America and Asia Pacific Earmarked for Exceptional Growth Trajectories - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 16, 2024
Biotechnology, Pharmaceutical, Health, Cystic fibrosis, Pseudomonas aeruginosa, Infection, Research, Carbapenem, Novartis, Cancer, Gilead Sciences, Acquisition, USD, Prevalence, Pharmaceutical industry

The "Global Pseudomonas Aeruginosa Infection Treatment Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Pseudomonas Aeruginosa Infection Treatment Market" report has been added to ResearchAndMarkets.com's offering.
  • The report uncloaks nuanced market trajectories and dynamics, providing insights into the promising developments toward antibiotic resistance.
  • Predicted to rise rapidly, the Asia Pacific market's growth orbit is propelled by heightened healthcare awareness and escalating healthcare investments.
  • North America and Asia Pacific regions earmarked for exceptional growth trajectories.

Capstan Therapeutics Appoints Ramin Farzaneh-Far, M.D., as Chief Medical Officer and Announces Key Business Leadership Promotion

Retrieved on: 
Monday, January 8, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, University, MAS, Autoimmune disease, Business, Drug development, Messenger, Acquisition, Roche, MBA, Therapy, UCB, David G. Booth, University College London, Growth, IPO, Cell, Patient, Corporate development, Gilead Sciences, UCSF, Senior, Pharmaceutical industry

Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through mRNA delivery using targeted lipid nanoparticles (tLNP), today announced the appointment of Ramin Farzaneh-Far, M.D., as Chief Medical Officer and the promotion of Miguel Arcinas to Senior Vice President, Corporate Development.

Key Points: 
  • Capstan Therapeutics, Inc. (“Capstan”), a biotechnology company dedicated to advancing in vivo reprogramming of cells through mRNA delivery using targeted lipid nanoparticles (tLNP), today announced the appointment of Ramin Farzaneh-Far, M.D., as Chief Medical Officer and the promotion of Miguel Arcinas to Senior Vice President, Corporate Development.
  • He previously led global clinical development programs at Akebia Therapeutics and Gilead Sciences.
  • “I am pleased to announce Miguel’s promotion in recognition of his contributions to the organization.”
    Mr. Arcinas joined Capstan in 2021 as the company’s Vice President of Corporate Development.
  • He has over 15 years of multi-disciplinary experience in biotech corporate strategy, business development, investor relations, and clinical operations.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Clarivate Identifies Thirteen Potential Blockbuster Drugs and Gamechangers in Annual Drugs to Watch Report

Retrieved on: 
Monday, January 8, 2024
GEJ, Immunoglobulin A, GPRC5D, Government, Trastuzumab, Daiichi Sankyo, DME, BRCA, FDA, Spacecraft, Health, Haemophilia, Abiraterone acetate, Infection, PDE, Crohn's disease, CLVT, Drug discovery, Breast cancer, Breast, Data, Budesonide, AMD, PARP, Metastasis, PDE4, DXD, Safety, NSCLC, Health care, RSV, DR, AstraZeneca, EMA, CRISPR, Chronic obstructive pulmonary disease, Adenocarcinoma, Multiple myeloma, Civil service commission, Artificial intelligence, Patient, Stada Arzneimittel, Intelligence, CD3, Ulcerative colitis, SCD, Lung cancer, European Commission, Sickle cell disease, Gilead Sciences, Respiratory syncytial virus, Research, Diabetic retinopathy, Mirikizumab, COPD, COVID-19, Conditional sentence, Genentech, Thalassemia, Organization, Zolbetuximab, ADC, Pharmaceutical industry

LONDON, Jan. 8, 2024 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual Drugs to Watch™ report. The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success. The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.

Key Points: 
  • The report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
  • The report, a key industry resource in the evolving healthcare landscape, has identified over 85 Drugs to Watch over the 11-year course of its publication.
  • Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year's Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes."
  • Included in Drugs to Watch 2023, a delayed U.S. launch meant that it remains a drug to watch for 2024.

Scorpion Therapeutics Appoints Adam Friedman, M.D., Ph.D., as Chief Executive Officer and Expands Leadership Team

Retrieved on: 
Thursday, January 4, 2024
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Atlas Venture, Massachusetts Institute of Technology, Atlas, Entrepreneurship, Culture, Food, Medicine, Princeton University, AstraZeneca, Drug development, Georgetown University, Marketing, Drug, Molecular biology, Black Majesty, Disease, Strategic management, Pediatrics, Therapy, Neoplasm, Senior, Stanford University, Brandeis University, Cancer, Business development, Doctor of Philosophy, Growth, Patient, Corporate development, Gilead Sciences, Boston, Harvard Medical School, Food and Drug Administration, Corporation, AbbVie, Pharmaceutical industry

In addition, the Company named Jeff Albers as Executive Chair and member of the Board of Directors.

Key Points: 
  • In addition, the Company named Jeff Albers as Executive Chair and member of the Board of Directors.
  • Mr. Albers currently serves as board chairman at Blueprint Medicines and board director at Kymera Therapeutics and Spyre Therapeutics.
  • Mark Chao, M.D., Ph.D., has been named Chief Medical Officer and Erica Jackson, Ph.D., has been promoted to Chief Discovery Officer.
  • Dr. Chao joins Scorpion from TenSixteen Bio, a precision therapeutics company where he served as Co-Founder and CEO.

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Retrieved on: 
Thursday, January 4, 2024
Assembly, Partnership, Outline, Biotechnology, HDV, HBV, Trial of the century, Hepatitis B, Viral, HSV, Patient, Gilead Sciences, Vaccine

Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D viruses

Key Points: 
  • Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D viruses
    Recently announced long-term partnership with Gilead Sciences, Inc. (Gilead) to address serious viral diseases expands and builds on the progress of Assembly Bio’s antiviral portfolio
    SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.
  • “We are thrilled with the rapid progress of multiple programs from our expanded antiviral pipeline, and plan to initiate clinical studies for four development candidates in 2024,” said Jason Okazaki, chief executive officer and president of Assembly Bio.
  • By the end of 2024:
    Two additional candidates are anticipated to enter the clinic:
    ABI-1179, the long-acting HSV helicase-primase inhibitor contributed by Gilead under the collaboration between Assembly Bio and Gilead; and
    ABI-6250, a small molecule orally-bioavailable hepatitis delta virus entry inhibitor.
  • Initial clinical data are expected to be available from both the ABI-5366 first-in-human clinical study and the ABI-4334 Phase 1b study.

Harpoon Therapeutics Strengthens Leadership Team

Retrieved on: 
Tuesday, December 26, 2023
Shearman & Sterling, Harpoon, Shearman, Accounting, Human, Talent management, Lundbeck Seattle Biopharmaceuticals, Intellectual property, Law, SAN, Therapy, Exelixis, University, Culture, General counsel, Growth, Human resources, Colgate University, Gilead Sciences, Employment, Management

SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer. Mr. Bucher and Ms. Chang are part of the executive management team and report directly to the Chief Executive Officer.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of James Bucher, J.D.
  • Mr. Bucher and Ms. Chang are part of the executive management team and report directly to the Chief Executive Officer.
  • “I am delighted to welcome Jim to the Harpoon leadership team and announce Wendy’s promotion.
  • In connection with Mr. Bucher’s appointment, Harpoon Therapeutics granted him an inducement non-qualified stock option to purchase an aggregate of 110,000 shares of Harpoon’s common stock.

HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences

Retrieved on: 
Thursday, December 21, 2023
Partnership, Food, Antigen, Hoʻokipa, Sale, Arenavirus, The Mark of Gideon, Common stock, Investigational New Drug, Equity, HIV, LCMV, Prospectus, Gilead Sciences, Security (finance), Pharmaceutical industry

In addition, HOOKIPA has the right, subject to certain terms and conditions, to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata participation in potential future equity raises.

Key Points: 
  • In addition, HOOKIPA has the right, subject to certain terms and conditions, to sell an additional approximately $8.75 million of common stock to Gilead as pro-rata participation in potential future equity raises.
  • The agreement with Gilead replaces the stock purchase agreement that Hookipa entered into with Gilead in 2022.
  • Following the completion of the stock purchase, Gilead’s ownership in HOOKIPA increased to 18,759,465 shares, or approximately 19.4% of HOOKIPA’s outstanding shares of Common Stock.
  • HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.